[go: up one dir, main page]

WO2020126968A3 - Urea derivatives for use against proliferative diseases - Google Patents

Urea derivatives for use against proliferative diseases Download PDF

Info

Publication number
WO2020126968A3
WO2020126968A3 PCT/EP2019/085239 EP2019085239W WO2020126968A3 WO 2020126968 A3 WO2020126968 A3 WO 2020126968A3 EP 2019085239 W EP2019085239 W EP 2019085239W WO 2020126968 A3 WO2020126968 A3 WO 2020126968A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
proliferative diseases
urea derivatives
use against
against proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/085239
Other languages
French (fr)
Other versions
WO2020126968A2 (en
Inventor
Nico BRÄUER
Alexander Helmut Michael EHRMANN
Matyas GORJANACZ
Carlo STRESEMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of WO2020126968A2 publication Critical patent/WO2020126968A2/en
Publication of WO2020126968A3 publication Critical patent/WO2020126968A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention covers urea compounds of general formula (I) in which R1, A and B are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
PCT/EP2019/085239 2018-12-20 2019-12-16 Urea derivatives Ceased WO2020126968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782890P 2018-12-20 2018-12-20
US62/782,890 2018-12-20

Publications (2)

Publication Number Publication Date
WO2020126968A2 WO2020126968A2 (en) 2020-06-25
WO2020126968A3 true WO2020126968A3 (en) 2020-07-30

Family

ID=69167775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/085239 Ceased WO2020126968A2 (en) 2018-12-20 2019-12-16 Urea derivatives

Country Status (1)

Country Link
WO (1) WO2020126968A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2946060T3 (en) 2018-08-17 2023-07-12 Novartis Ag Urea compounds and compositions as SMARCA2/BRM-ATPASA inhibitors
WO2021042022A1 (en) * 2019-08-30 2021-03-04 University Of Rochester Septin inhibitors for treatment of cancers
WO2021207343A1 (en) * 2020-04-08 2021-10-14 Rheos Medicines, Inc. Malt1 inhibitors and uses thereof
CZ309190B6 (en) * 2020-10-13 2022-04-27 Ústav experimentální botaniky AV ČR, v. v. i. Substances for plant biotechnology based on 1-phenyl-3-yl-urea, preparations containing them and their use
CN112641782B (en) * 2020-12-29 2022-02-11 北京鑫开元医药科技有限公司 FGFR4 inhibitor preparation composition, preparation method and application thereof
CN112279834B (en) * 2020-12-29 2021-04-09 北京鑫开元医药科技有限公司 FGFR4 inhibitor, preparation method, pharmaceutical composition and application thereof
WO2023283921A1 (en) * 2021-07-16 2023-01-19 北京深蓝泰医药科技有限公司 Dpd inhibitor, and pharmaceutical composition and use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193788A (en) * 1977-10-08 1980-03-18 Yo Isogai N-(2-Chloro-4-pyridyl)ureas
US4279639A (en) * 1978-11-02 1981-07-21 Toshihiko Okamoto N-(2-Substituted-4-pyridyl)ureas and thioureas as well as plant growth regulators containing same, and method for using compounds as plant growth regulators
US4308054A (en) * 1979-11-02 1981-12-29 Yo Isogai N-(2,6-Disubstituted-4-pyridyl)-N'-phenylureas
WO1984003884A1 (en) * 1983-03-29 1984-10-11 Fmc Corp N-phenyl-n'-(pyridinyl-n-oxide)urea plant regulators
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ES2201909A1 (en) * 2002-06-06 2004-03-16 Universitat De Valencia Estudi General. Fluorinated N-(2-chloropyridin-4-yl)-N'-phenylureas and N-(3-nitrophenyl)-N'-phenylureas are used as promoters of growth of fruit in cultivation of Actinidia deliciosa
ES2209622A1 (en) * 2002-06-06 2004-06-16 Universitat De Valencia Estudi General FUNGICIDES BASED ON DERIVATIVES OF N- (3-NITROFENIL) -N'-FENIL-, N- (2-CHLOROPIRIDIN-4-IL) -N'-PHENYL-Y N- (1,2,3-TIADIAZOL-5 -IL) -N'-FENIL-UREAS FLUORATED FOR USE IN HORTICOL CROPS AND ORNAMENTAL PLANTS.
WO2006018662A2 (en) * 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
WO2012103523A2 (en) * 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193788A (en) * 1977-10-08 1980-03-18 Yo Isogai N-(2-Chloro-4-pyridyl)ureas
US4279639A (en) * 1978-11-02 1981-07-21 Toshihiko Okamoto N-(2-Substituted-4-pyridyl)ureas and thioureas as well as plant growth regulators containing same, and method for using compounds as plant growth regulators
US4308054A (en) * 1979-11-02 1981-12-29 Yo Isogai N-(2,6-Disubstituted-4-pyridyl)-N'-phenylureas
WO1984003884A1 (en) * 1983-03-29 1984-10-11 Fmc Corp N-phenyl-n'-(pyridinyl-n-oxide)urea plant regulators
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
ES2201909A1 (en) * 2002-06-06 2004-03-16 Universitat De Valencia Estudi General. Fluorinated N-(2-chloropyridin-4-yl)-N'-phenylureas and N-(3-nitrophenyl)-N'-phenylureas are used as promoters of growth of fruit in cultivation of Actinidia deliciosa
ES2209622A1 (en) * 2002-06-06 2004-06-16 Universitat De Valencia Estudi General FUNGICIDES BASED ON DERIVATIVES OF N- (3-NITROFENIL) -N'-FENIL-, N- (2-CHLOROPIRIDIN-4-IL) -N'-PHENYL-Y N- (1,2,3-TIADIAZOL-5 -IL) -N'-FENIL-UREAS FLUORATED FOR USE IN HORTICOL CROPS AND ORNAMENTAL PLANTS.
WO2006018662A2 (en) * 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
WO2012103523A2 (en) * 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JULIEN P. N. PAPILLON ET AL: "Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 22, 19 October 2018 (2018-10-19), US, pages 10155 - 10172, XP055619669, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01318 *
KOPECNY D ET AL: "Phenyl- and benzylurea cytokinins as competitive inhibitors of cytokinin oxidase/dehydrogenase: A structural study", BIOCHIMIE, MASSON, PARIS, FR, vol. 92, no. 8, 1 August 2010 (2010-08-01), pages 1052 - 1062, XP027141295, ISSN: 0300-9084, [retrieved on 20100515] *
SHAN YUANYUAN ET AL: "Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, ELSEVIER, NL, vol. 24, no. 4, 23 December 2015 (2015-12-23), pages 750 - 758, XP029399995, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2015.12.038 *
TOSHIHIKO OKAMOTO ET AL: "4-Pyridylureas are surprisingly potent cytokinins. The structure-activity relationship.", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 29, no. 12, 1 January 1981 (1981-01-01), JP, pages 3748 - 3750, XP055670855, ISSN: 0009-2363, DOI: 10.1248/cpb.29.3748 *
ZHONG-WEI HOU ET AL: "Electrochemical C-H/N-H Functionalization for the Synthesis of Highly Functionalized (Aza)indoles", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 55, no. 32, 1 August 2016 (2016-08-01), DE, pages 9168 - 9172, XP055671001, ISSN: 1433-7851, DOI: 10.1002/anie.201602616 *
ZHONG-WEI HOU ET AL: "Supporting Information Electrochemical C À H/N À H Functionalization for the Synthesis of Highly Functionalized (Aza)indoles Contents Page", ANGEWANDTE CHEMIE - INTERNATIONAL EDITION, vol. 128, no. 32, 30 May 2016 (2016-05-30), pages S1 - S216, XP055671004 *

Also Published As

Publication number Publication date
WO2020126968A2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
WO2020083971A3 (en) New anthelmintic compounds
MX2020001403A (en) Quinoline derivatives for treating infections with helminths.
PH12019502851A1 (en) New azaquinoline derivatives
MX2020001404A (en) Dihydrooxadiazinones.
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
SA522432734B1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12020551891A1 (en) New quinoline derivatives
WO2016020320A8 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
PH12019502365A1 (en) New bicyclic pyrazole derivatives
WO2017198341A8 (en) Macrocyclic indole derivatives
CR20230485A (en) Phosphorus derivatives as novel sos1 inhibitors
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
SA518400501B1 (en) [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
MX2024003015A (en) NEW QUINOLINE DERIVATIVES.
EP3795170A4 (en) Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases
WO2018114677A3 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3868393A4 (en) Pharmaceutical composition for treating retinal diseases, comprising nkx3.2 and fragment thereof as active ingredients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19836792

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19836792

Country of ref document: EP

Kind code of ref document: A2